Arnab Bhattacharjee

Dr. Arnab Bhattacharjee


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ABArnab Bhattacharjee
Arnab Bhattacharjee
SRStefanie Reuter
Stefanie Reuter
ETEszter Trojnár
Eszter Trojnár
RKRobert Kolodziejczyk
Robert Kolodziejczyk
HSHarald Seeberger
Harald Seeberger
TJT. Sakari Jokiranta
T. Sakari Jokiranta
Atypical hemolytic uremic syndrome (aHUS) is characterized by complement attack against host cells due to mutations in complement proteins or autoantibodies against complement factor H (CFH). It is unknown why nearly all patients with autoimmune aHUS lack CFHR1 (CFH-related protein-1). These patients have autoantibodies against CFH domains 19 and 20 (CFH19–20), which are nearly identical to CFHR1 domains 4 and 5 (CFHR14–5). Here, binding site mapping of autoantibodies from 17 patients using mutant CFH19–20 constructs revealed an autoantibody epitope cluster within a loop on domain 20, next to the two buried residues that are different in CFH19–20 and CFHR14–5. The crystal structure of CFHR14–5 revealed a difference in conformation of the autoantigenic loop in the C-terminal domains of CFH and CFHR1, explaining the variation in binding of autoantibodies from some aHUS patients to CFH19–20 and CFHR14–5. The autoantigenic loop on CFH seems to be generally flexible, as its conformation in previously published structures of CFH19–20 bound to the microbial protein OspE and a sialic acid glycan is somewhat altered. Cumulatively, our data suggest that association of CFHR1 deficiency with autoimmune aHUS could be due to the structural difference between CFHR1 and the autoantigenic CFH epitope, suggesting a novel explanation for CFHR1 deficiency in the pathogenesis of autoimmune aHUS.

18 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MGMelissa A. Graewert
Melissa A. Graewert
MVMaria Volkova
Maria Volkova
KJKlara Jonasson
Klara Jonasson
JMJuha A. E. Määttä
Juha A. E. Määttä
TGTobias Gräwert
Tobias Gräwert
HHHenri J. Huttunen
Henri J. Huttunen
Cerebral dopamine neurotrophic factor (CDNF) is an unconventional neurotrophic factor that is a disease-modifying drug candidate for Parkinson’s disease. CDNF has pleiotropic protective effects on stressed cells, but its mechanism of action remains incompletely understood. Here, we use state-of-the-art advanced structural techniques to resolve the structural basis of CDNF interaction with GRP78, the master regulator of the unfolded protein response (UPR) pathway. Subsequent binding studies confirm the obtained structural model of the complex, eventually revealing the interaction site of CDNF and GRP78. Finally, mutating the key residues of CDNF mediating its interaction with GRP78 not only results in impaired binding of CDNF but also abolishes the neuroprotective activity of CDNF-derived peptides in mesencephalic neuron cultures. These results suggest that the molecular interaction with GRP78 mediates the neuroprotective actions of CDNF and provide a structural basis for development of next generation CDNF-based therapeutic compounds against neurodegenerative diseases.

31 August 2010 in Molecular Immunology
Verified
Journal Article
Closed access
TKTommi Kajander
Tommi Kajander
ABArnab Bhattacharjee
Arnab Bhattacharjee
MLMarkus J. Lehtinen
Markus J. Lehtinen
SHSatu Hyvärinen
Satu Hyvärinen
ELElisa Leung
Elisa Leung
TJT. Sakari Jokiranta
T. Sakari Jokiranta

31 August 2010 in Molecular Immunology
Verified
Journal Article
Closed access
JSJutamas Shaughnessy
Jutamas Shaughnessy
SRSanjay Ram
Sanjay Ram
ABArnab Bhattacharjee
Arnab Bhattacharjee
CTConnie Tran
Connie Tran
GHGabor Horvath
Gabor Horvath
PRPeter A. Rice
Peter A. Rice

27 February 2026 in Viruses
Verified
Journal Article
Open access
PDF file
Mikael SkurnikMikael Skurnik
Mikael Skurnik
RTRahime Tetik
Rahime Tetik
MQMuhammad Suleman Qasim
Muhammad Suleman Qasim
JSJana Sachsenröder
Jana Sachsenröder
RDRalf Dieckmann
Ralf Dieckmann
ABArnab Bhattacharjee
Arnab Bhattacharjee
The bacterium Yersinia enterocolitica serotype O:3 is targeted by two distinct agents, the bacteriophage φR1-37 and the bacteriocin-like enterocoliticin (a tailocin), which both utilize the lipopolysaccharide (LPS) outer core (OC) hexasaccharide as their primary host receptor. In order to understand this convergent recognition mechanism, we first characterized the enterocoliticin system, reporting the complete sequence of its large, biosynthetic gene cluster. Most of the 42 predicted gene products were functionally annotated by homology to known gene products. We then focused on identifying the receptor-binding proteins (RBPs) responsible for host attachment of both agents in order to elucidate a possible shared mechanism of binding. For phage φR1-37, the receptor binding complex was identified as the inseparable Gp298 tail fiber protein and its Gp297 trimerization chaperone, confirming its function as the RBP. Based on sequence identity with Gp298, the Orf39 gene product of the enterocoliticin cluster was predicted to be its corresponding RBP. An analytical comparison of the predicted RBPs revealed a highly conserved homologous region spanning 80–85 amino acid residues, which presents the only structural explanation for their identical receptor specificity. To resolve the binding mechanism, we generated high-confidence trimeric structural models for the Gp298 and Orf39 proteins using AlphaFold3-multimer. These models validated the high structural similarity of the RBP domains, despite global dissimilarity of the complete trimeric structures. Further docking simulations with a pentasaccharide ligand (generated by CarbBuilder) provided suggestive molecular models for the protein-carbohydrate interactions within the OC region. Intriguingly, a database search using the identified binding site motif revealed their wide and diverse presence in various phage tail proteins, suggesting that this motif is a specialized, common structure for carbohydrate recognition. This work identifies a conserved, novel sugar-binding motif as the molecular basis of host recognition for these key anti-Yersinia biologics.